CPC A61K 31/4985 (2013.01) [A61K 31/47 (2013.01); A61K 31/519 (2013.01); A61P 11/00 (2018.01); A61K 45/06 (2013.01); A61K 2121/00 (2013.01)] | 24 Claims |
1. A method of reducing pulmonary exacerbations in a cystic fibrosis patient, wherein the patient is undergoing concomitant treatment with a CFTR modulator and wherein the patient has an FEV1pp greater than or equal to about 68% at baseline, the method comprising orally administering to the patient acebilustat at a total daily dose of about 100 mg or less, and wherein the CFTR modulator is selected from the group consisting of ivacaftor, lumacaftor, tezacaftor, VX-445, VX-659, VX-440 and VX-152, or a combination of any of thereof.
|